Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7


Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.

Löhr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Fölsch UR, Jäger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP; CT4001 Study Group.

Ann Oncol. 2012 May;23(5):1214-22. doi: 10.1093/annonc/mdr379. Epub 2011 Sep 6.


Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M.

World J Gastroenterol. 2015 Apr 28;21(16):4788-801. doi: 10.3748/wjg.v21.i16.4788. Review.


Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.

Shelley M, Cleves A, Wilt TJ, Mason M.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. Review.


Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.

Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH.

Drug Des Devel Ther. 2016 Jun 13;10:1961-72. doi: 10.2147/DDDT.S105442. eCollection 2016. Review.


Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.

Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA.

Target Oncol. 2017 Jun;12(3):309-321. doi: 10.1007/s11523-017-0486-5. Review.


Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.

Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ.

BMC Cancer. 2014 Jun 27;14:471. doi: 10.1186/1471-2407-14-471. Review.


nab-Paclitaxel for the treatment of pancreatic cancer.

Kim G.

Cancer Manag Res. 2017 Mar 16;9:85-96. doi: 10.2147/CMAR.S127840. eCollection 2017. Review.

Supplemental Content

Support Center